Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients With Mild or Moderate Hemophilia A Without FVIII Inhibitors

NCT04158648 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04158648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04158648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients With Mild or Moderate Hemophilia A Without FVIII Inhibitors
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
February 10, 2020
Completion date
December 19, 2025
Enrollment
73 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a, mild hereditary factor viii deficiency disease without inhibitor, moderate hereditary factor viii deficiency disease without inhibitor